Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year - Seite 2
In FRONTIER 2, JNJ-2113 maintained high rates of skin clearance through 52 weeks in adults with moderate-to-severe plaque psoriasis. In the five JNJ-2113 treatment groups, response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks). Similar to the primary endpoint, responses were maintained through Week 52 for all five JNJ-2113 treatment groups for the key secondary endpoints of PASI 90 (59.5% at 16 weeks and 64.3% at 52 weeks), PASI 100 (40.5% at 16 weeks and 40.5% at 52 weeks), Investigator's Global Assessment (IGA) 0/1 (64.3% at 16 weeks and 73.8% at 52 weeks) and IGA 0 (45.2% at 16 weeks and 42.9% at 52 weeks).
Lesen Sie auch
A summary of PASI responder data from the FRONTIER 2 study at Week 52:
# |
Cohort |
PASI 75 (%) |
PASI 90 (%) |
PASI 100 (%) |
1 |
25 mg daily (n=43) |
48.8 |
27.9 |
14.0 |
2 |
25 mg twice daily (n=41) |
58.5 |
36.6 |
17.1 |
3 |
50 mg daily (n=43) |
69.8 |
41.9 |
20.9 |
4 |
100 mg daily (n=43) |
65.1 |
51.2 |
25.6 |
5 |
100 mg twice daily (n=42) |